Edgewise Therapeutics Price Target Raised to $59 Following Positive HCM Trial Data
RBC Capital raised its price target for Edgewise Therapeutics (EWTX) from $48 to $59, citing positive results from the company's Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. The firm maintains an Outperform rating and highlights potential improvements in therapy usability based on these findings.
Tickers: $EWTX
Topics: analyst report Edgewise Therapeutics EWTX HCM clinical trials price target upgrade